A preoperative nomogram identifying decreased risk of positive pelvic lymph nodes in patients with prostate cancer.

PURPOSE We developed a preoperative nomogram for prediction of lymph node metastases in patients with clinically localized prostate cancer. MATERIALS AND METHODS The study was a retrospective, nonrandomized analysis of 7,014 patients treated with radical prostatectomy at 6 institutions between 1985 and 2000. Exclusion criteria consisted of preoperative androgen ablation therapy, salvage radical prostatectomy and pretreatment prostate specific antigen (PSA) greater than 50 ng/ml. Preoperative predictors of lymph node metastases consisted of pretreatment PSA, clinical stage (1992 TNM) and biopsy Gleason sum. These predictors were used in logistic regression analysis based nomograms to predict the probability of lymph node metastases. RESULTS Overall 5,510 patients with complete clinical and pathological information were included in the study. Lymph nodes metastases were present in 206 patients (3.7%). Pretreatment PSA, biopsy Gleason sum, clinical stage and institution represented predictors of lymph node status (p <0.001). Bootstrap corrected predictive accuracy of the 3-variable nomogram (clinical stage, Gleason sum and PSA) was 0.76. Inclusion of a fourth variable, which accounts for institutional differences in lymph node metastases, yielded an area under the receiver operating characteristics curve of 0.78. The negative predictive value of our nomograms was 0.99 when they predicted 3% or less chance of positive lymph nodes. CONCLUSIONS Using clinical information, we produced 2 calibrated and validated nomograms, which accurately predict pathologically negative lymph nodes in men with localized prostate cancer who are candidates for radical prostatectomy.

[1]  M. Kattan,et al.  Has there been a recent shift in the pathological features and prognosis of patients treated with radical prostatectomy? , 1997, The Journal of urology.

[2]  A W Partin,et al.  Serum PSA after anatomic radical prostatectomy. The Johns Hopkins experience after 10 years. , 1993, The Urologic clinics of North America.

[3]  P. Scardino,et al.  Prognostic significance of lymph nodal metastases in prostate cancer. , 1989, The Journal of urology.

[4]  C. Brendler,et al.  Staging pelvic lymphadenectomy for carcinoma of the prostate risk versus benefit. , 1980, The Journal of urology.

[5]  A. Haese*,et al.  Validation of a biopsy‐based pathologic algorithm for predicting lymph node metastases in patients with clinically localized prostate carcinoma , 2002, Cancer.

[6]  Frank E. Harrell,et al.  Regression Modeling Strategies: With Applications to Linear Models, Logistic Regression, and Survival Analysis , 2001 .

[7]  T. Shankey,et al.  Limited efficacy of preoperative computed tomographic scanning for the evaluation of lymph node metastasis in patients before radical prostatectomy. , 1996, Urology.

[8]  H. Levin,et al.  Open pelvic lymph node dissection for prostate cancer: a reassessment. , 1995, Urology.

[9]  D. Bostwick,et al.  Eliminating the need for bilateral pelvic lymphadenectomy in select patients with prostate cancer. , 1994, The Journal of urology.

[10]  R. Gittes,et al.  Prostatic carcinoma: incidence and location of unsuspected lymphatic metastases. , 1976, The Journal of urology.

[11]  S. Al-Askari,et al.  Extended pelvic lymphadenectomy for prostatic cancer. , 1979, The Journal of urology.

[12]  P. Narayan,et al.  Utility of preoperative serumprostate-specific antigen concentration and biopsy Gleason score in predicting risk of pelvic lymph node metastases in prostate cancer , 1994 .

[13]  G. Williams,et al.  Intraoperative and early complications of staging pelvic lymph node dissection in prostatic adenocarcinoma. , 1990, Urology.

[14]  A W Partin,et al.  Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update. , 1997, JAMA.

[15]  D. Bostwick,et al.  Risk of prostate carcinoma death in patients with lymph node metastasis , 2001, Cancer.

[16]  J. Bishoff,et al.  Pelvic lymphadenectomy can be omitted in selected patients with carcinoma of the prostate: development of a system of patient selection. , 1995, Urology.

[17]  A. Heidenreich,et al.  Extended pelvic lymphadenectomy in patients undergoing radical prostatectomy: high incidence of lymph node metastasis. , 2002, The Journal of urology.

[18]  G H Hinkle,et al.  Multicenter radioimmunoscintigraphic evaluation of patients with prostate carcinoma using indium‐111 capromab pendetide , 1998, Cancer.

[19]  Stefan Conrad,et al.  Prospective validation of an algorithm with systematic sextant biopsy to predict pelvic lymph node metastasis in patients with clinically localized prostatic carcinoma. , 2002, The Journal of urology.

[20]  J. Cadeddu,et al.  Stage D1 (T1-3, N1-3, M0) prostate cancer: a case-controlled comparison of conservative treatment versus radical prostatectomy. , 1997, Urology.